Welcome to our dedicated page for Aptargroup news (Ticker: ATR), a resource for investors and traders seeking the latest updates and insights on Aptargroup stock.
AptarGroup, Inc. (NYSE: ATR) generates news across drug delivery, digital health and consumer dispensing technologies. As a global company serving pharmaceutical, beauty, food, beverage, personal care and home care markets, its announcements often highlight new delivery systems, clinical collaborations, acquisitions and financial updates that are relevant to investors and industry observers.
Recent news has featured Aptar Pharma’s nasal and ophthalmic platforms, such as LuerVax and Spray Divider being used in a Phase II clinical trial of an intranasal COVID-19 vaccine candidate, and Bidose liquid nasal spray systems delivering an FDA-approved treatment for paroxysmal supraventricular tachycardia. The company also reports on developments in eye care, including its Beat the Blink technology and preservative-free multidose dispensers, as well as broader portfolios of ophthalmic solutions.
Aptar’s Digital Health division appears frequently in updates related to connected health tools and data-driven care. Examples include the integration of the Migraine Buddy app with biometric data from wearable devices and FDA 510(k) clearance for HeroTracker Sense, a connected add-on for metered-dose inhalers within a respiratory disease management platform.
Investors following ATR news will also find earnings releases, segment performance commentary, conference participation announcements and information on capital markets activity, such as senior notes offerings. This news page brings together these items so readers can review Aptar’s latest product milestones, partnerships, digital health initiatives and financial communications in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AptarGroup, Inc. (NYSE: ATR) has announced a quarterly cash dividend of $0.38 per share, with a payment date set for May 25, 2023 for shareholders on record as of May 4, 2023. The company, based in Crystal Lake, Illinois, specializes in drug delivery and consumer product dispensing solutions across various markets, including pharmaceuticals and personal care. Additionally, Aptar will conduct a conference call on April 28, 2023, at 8:00 a.m. CT to discuss its Q1 2023 results. Interested parties can access the live webcast through the company's Investors page.
AptarGroup, Inc. (NYSE: ATR) has released a recast of financial information following a strategic segment realignment of its reporting segments, focusing on Aptar Closures and Aptar Beauty. The recast covers the past two years of performance for these segments, while the financials for Aptar Pharma remain unchanged. The detailed financial information is accessible in the company's Form 8-K filed on April 13, 2023. Aptar is recognized for its innovative solutions in drug delivery, consumer product dispensing, and active material sciences, catering to various industries including pharmaceuticals and beauty. Headquartered in Crystal Lake, Illinois, Aptar employs 13,500 people across 20 countries.
AptarGroup, Inc. (NYSE: ATR) has been recognized on the CDP Supplier Engagement Leaderboard for the third consecutive year, positioning itself among the top 8% of companies evaluated for climate change engagement. Aptar received an ‘A’ rating, surpassing the North America regional average of ‘C’ and the plastic product manufacturing average of ‘C-‘. The company actively collaborates with suppliers to reduce emissions, focusing on the significant scope 3 emissions from purchased goods, particularly plastics. Additionally, Aptar aims to enhance its supply chain diversity through its newly launched Supplier Diversity Program.
AptarGroup, Inc. (NYSE: ATR) has updated its science-based targets for emissions reduction, aligning with a goal to limit global temperature rise to 1.5° Celsius by 2030. Originally set in 2020 to align with a well below 2°C scenario, the targets have been revised to demonstrate increased ambition. The company aims to reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 82% and Scope 3 emissions by 14% by 2030, using 2019 as the base year. Additionally, Aptar plans to source 100% renewable electricity by 2030. These commitments have been validated by the Science Based Targets initiative (SBTi). Aptar emphasizes its commitment to sustainability through innovative practices.
Summary not available.
FAQ
What is the current stock price of Aptargroup (ATR)?
What is the market cap of Aptargroup (ATR)?
